EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Duloxetine as a gut-brain axis modulator in irritable bowel syndrome: neuroimmune, microbiota, and pharmacogenomic perspectives

Mokhtar Rejili, Aya M Mustafa, Hayder M Al-Kuraishy, Nawar R Hussein, Thabat J Al-Maiahy, Ali I Al-Gareeb, Ali K Albuhadily, Gaber El-Saber Batiha

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-026-05419-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Mokhtar Rejili und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, College of Sciences, Imam Mohammad Ibn Saud Islamic University (IMSIU), 11623, Riyadh, Saudi Arabia. msrejili@imamu.edu.sa. Hauptthemen laut MEDLINE: Duloxetine Hydrochloride, Irritable Bowel Syndrome, Gastrointestinal Microbiome, Brain-Gut Axis. Die Arbeit nennt 179 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To provide an updated and integrative evaluation of duloxetine as a potential therapeutic agent for irritable bowel syndrome (IBS), with emphasis on its mechanisms of action across the gut-brain axis. The review addresses the key research question: Can duloxetine, beyond its antidepressant effects, modulate neuroimmune, microbial, and pharmacogenomic factors relevant to IBS, particularly pain-predominant subtypes? This narrative review provides a targeted synthesis of selected preclinical, clinical, and translational literature addressing duloxetine as a potential gut-brain axis modulator in irritable bowel syndrome. Evidence related to neuroimmune mechanisms, microbiota-related pathways, pharmacogenomic considerations, and clinical studies was narratively summarized. Evidence indicates that duloxetine modulates serotonergic and noradrenergic neurotransmission, decreases visceral hypersensitivity, and attenuates neuroinflammation via inhibition of microglial P2X4/NF-κB signaling. Duloxetine also shifts cytokine balance toward an anti-inflammatory profile (↑ IL-10, ↓ IL-6, ↓ TNF-α). Emerging data suggest additional benefits through modulation of gut microbiota composition, enhancement of short-chain fatty acid (SCFA) production, and improvement of intestinal barrier integrity. Pharmacogenomic factors, especially CYP2D6 and CYP1A2 polymorphisms, significantly influence duloxetine metabolism and therapeutic response. Compared with TCAs and SSRIs, duloxetine shows more favorable efficacy in relieving combined gastrointestinal and psychological symptoms with fewer sexual side effects. Duloxetine exhibits multifaceted actions that extend beyond mood regulation, positioning it as a promising but still investigational GBA-directed option dual-action therapy within the gut-brain axis framework. The collective findings support the need for biomarker-guided clinical trials incorporating microbiota profiling, cytokine signatures, and pharmacogenetic testing to validate duloxetine's role in precision-medicine-based IBS management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Duloxetine HydrochlorideIrritable Bowel SyndromeGastrointestinal MicrobiomeBrain-Gut AxisSerotonin and Noradrenaline Reuptake InhibitorsHumansAnimalsPharmacogeneticsNeuroimmunomodulationBrain

Stichwörter der Autor:innen

DuloxetineGut microbiotaGut-brain axisIrritable bowel syndromeNeuroimmune modulationVisceral hypersensitivity

Substanzen

Duloxetine HydrochlorideSerotonin and Noradrenaline Reuptake Inhibitors

Autor:innen und Institutionen

  • Department of Biology, College of Sciences, Imam Mohammad Ibn Saud Islamic University (IMSIU), 11623, Riyadh, Saudi Arabia. msrejili@imamu.edu.sa.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, 11829, Egypt. aya-mustafa@eru.edu.eg.
  • Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, P.O. Box 14132, Baghdad, Iraq.
  • College of Pharmacy, Al-Farahidi University, Baghdad, Iraq.
  • Department of Gynecology and Obstetrics, College of Medicine, Al-Mustansiriya University, P.O. Box 14132, Baghdad, Iraq.
  • Jabir Ibn Hayyan Medical University, Al-Ameer Qu, PO. Box 13, Kufa, Najaf, Iraq.

Zitieren

APA

Rejili, M., Mustafa, A. M., Al-Kuraishy, H. M., Hussein, N. R., Al-Maiahy, T. J., Al-Gareeb, A. I., Albuhadily, A. K., & Batiha, G. E. (2026). Duloxetine as a gut-brain axis modulator in irritable bowel syndrome: neuroimmune, microbiota, and pharmacogenomic perspectives. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05419-1

Vancouver

Rejili M, Mustafa AM, Al-Kuraishy HM, Hussein NR, Al-Maiahy TJ, Al-Gareeb AI, et al. Duloxetine as a gut-brain axis modulator in irritable bowel syndrome: neuroimmune, microbiota, and pharmacogenomic perspectives. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05419-1

BibTeX
@article{Rejili2026,
  author = {Rejili, Mokhtar and Mustafa, Aya M and Al-Kuraishy, Hayder M and Hussein, Nawar R and Al-Maiahy, Thabat J and Al-Gareeb, Ali I and Albuhadily, Ali K and Batiha, Gaber El-Saber},
  title = {Duloxetine as a gut-brain axis modulator in irritable bowel syndrome: neuroimmune, microbiota, and pharmacogenomic perspectives},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05419-1}
}
Kostenlos starten →